Edition:
United Kingdom

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

22.07USD
5:37pm BST
Change (% chg)

$0.33 (+1.52%)
Prev Close
$21.74
Open
$21.93
Day's High
$22.19
Day's Low
$21.91
Volume
524,074
Avg. Vol
2,423,633
52-wk High
$25.96
52-wk Low
$10.85

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $18,714.96
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.09
Yield (%): 6.93

Financials

  TEVA.N Industry Sector
P/E (TTM): -- 30.95 32.69
EPS (TTM): -6.03 -- --
ROI: -10.61 14.77 14.32
ROE: -24.14 16.27 16.04

Brazilian drugmaker EMS interested in Europe's Medis -paper

SAO PAULO, Oct 2 Brazilian drugmaker EMS is interested in acquiring Iceland-based generic drugmaker Medis, put on sale by Israel's Teva Pharmaceutical Industries Ltd a year ago, Brazilian newspaper O Estado de S. Paulo reported on Tuesday.

02 Oct 2018

U.S. judge dismisses Teva lawsuits against Lilly on migraine drug

BOSTON A federal judge on Thursday dismissed a pair of patent infringement lawsuits by Teva Pharmaceutical Industries Ltd that sought to block Eli Lilly and Co from bringing its migraine drug Emgality to market in the United States.

28 Sep 2018

U.S. judge dismisses Teva lawsuits against Lilly on migraine drug

BOSTON, Sept 27 A federal judge on Thursday dismissed a pair of patent infringement lawsuits by Teva Pharmaceutical Industries Ltd that sought to block Eli Lilly and Co from bringing its migraine drug Emgality to market in the United States.

27 Sep 2018

U.S. regulator approves Teva migraine drug, shares rise

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company's new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

15 Sep 2018

UPDATE 2-U.S. regulator approves Teva migraine drug, shares rise

Sept 14 Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company's new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

15 Sep 2018

U.S. health regulator approves Teva's migraine drug

Sept 14 Israeli drugmaker Teva Pharmaceutical Industries on Friday received approval https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf?utm_campaign=FDA%20approves%20new%20drug%20for%20preventive%20treatment%20of%20migraines%20in%20adults-%20Drug&utm_medium=email&utm_source=Eloqua&elqTrackId=D3AA52FF20AD693CDFB23B3D6D50FBDF&elq=c7fbdf48175441979bbf02cf84407b39&elqaid=5102&elqat=1&elqCampaignId=4076 from the U.S. Food and Drug Administration to sell its new mi

14 Sep 2018

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

12 Sep 2018

UPDATE 1-Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

12 Sep 2018

Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

12 Sep 2018

Orexo soars after winning opioid drug appeal against Teva

A U.S. appeals court on Monday revived Swedish pharmaceutical company Orexo AB's lawsuit accusing a unit of Israel's Teva Pharmaceutical Industries Ltd of infringing a patent for its opioid addiction drug Zubsolv.

10 Sep 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF84.08 +1.62
Biogen Inc (BIIB.OQ) $333.98 +5.57

Earnings vs. Estimates